IRA, Istituto Ricerche Applicate, is Supporting Partner of MDG 2025, the reference event for medical devices organized by Complife Group. Since 1983, the company has supported the market with research, development, and manufacturing, focusing on quality, safety, and compliance.

Who is IRA – Istituto Ricerche Applicate

Founded in 1983, IRA is an Italian company specialized in research, development, and contract manufacturing of medical devices, dermocosmetic products, and food supplements. For over forty years, it has combined scientific expertise, industrial capability, and regulatory oversight, managing the entire product lifecycle: from initial concept to market release.

The company operates with a strong focus on safety, performance, and technical documentation, thanks to structured internal processes for clinical evaluation and risk management.

IRA offers integrated operational support for contract manufacturing of medical devices, including technology transfer, design and optimization of production processes, as well as development of dedicated control methods. The company's approach ensures complete supply chain management, from sourcing and supplier qualification to finished product release, ensuring full compliance with quality standards and applicable regulatory requirements.

Its mission is clear: to transform research into reliable, market-ready solutions, supporting companies in their development journey with a scientific and pragmatic approach. The vision guiding IRA is to be recognized as a national and international reference point for applied innovation, providing analytical and technological tools that help companies anticipate future challenges and translate them into competitive advantage.

"Since 1983, being always one idea ahead means for us investing in quality and responding innovatively to people's needs. Our mission is to imagine new scenarios and make them possible." (quoted from IRA's official website)

 

The collaboration with IRA – Supporting Partner at MDG 2025

IRA is a strategic partner that transforms scientific knowledge into immediately applicable solutions.

The partnership with MDG - MedGenerAction 2025 stems from shared fundamental values: the pursuit of excellence, trust in innovation as a driver of progress, and ethical commitment to sustainable long-term impact. Both organizations promote the culture of safe products,

traceable and compliant, creating a meeting point between research, regulation, and industry. In an edition dedicated to innovation, digitalization, and sustainability, IRA brings to MDG 2025 its most concrete contribution:

  • experience with CE-marked devices
  • solid regulatory expertise
  • a rigorous approach to compliance and risk management

All elements that make it an ideal ally for companies that want to grow in compliance with requirements and with controlled development timelines. Being Supporting Partner of MDG 2025 means for IRA reaffirming a principle that has always guided its activity: the synergy between research and application is the key to building the future of the medical sector.

Companies interested in developing or industrializing medical devices with a rigorous approach to compliance can rely on IRA's experience and methodology.

(For information or joint projects, it is possible to contact the IRA group to explore dedicated pathways for industrialization and manufacturing of medical devices, with specialized technical support aimed at CE marking readiness and subsequent market placement.)

Sponsored content created in collaboration with the Supporting Partner.

 

Who we are

Complife Group is an international group offering consulting and testing services for the Health & Care sector (cosmetics, supplements, medical devices, pharmaceuticals). For more information: www.complifegroup.com

Thema was founded in Imola in 2007, providing consulting and training in Quality & Regulatory Affairs for the medical sector. Since 2021, it has been part of the Complife Group. Info: www.thema-med.com